Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Nanomix Signs Exclusive Glucose Detection Licensing Agreement With MysticMD

Abstract:
Nanomix Inc., a leading electronic detection company commercializing high-value diagnostic and monitoring applications, today announced an exclusive licensing agreement with MysticMD Inc., a provider of proprietary nano-coatings. Per this agreement, MysticMD will provide Nanomix with intellectual property related to the use of nano-ink for glucose test strip technology. This builds upon earlier work between the two organizations to optimize the technology and explore partnering opportunities.

Nanomix Signs Exclusive Glucose Detection Licensing Agreement With MysticMD

EMERYVILLE, CA | Posted on November 5th, 2007

David Macdonald, Nanomix CEO, said, "We are pleased to have partnered with MysticMD, and believe that our collaboration will create better performing glucose test strips at a lower cost."

Heidi Douglas, co-founder and CEO of MysticMD, said, "We are excited to be working with Nanomix, as they are uniquely positioned to make best use of this IP in product development. With Nanomix' expertise in the area of detection devices, we feel confident that this partnership will enable us to bring this technology to market quickly and effectively through broader collaborations with market leaders."

####

About Nanomix Inc.
Nanomix is a leading electronic detection company launching detection devices based on Sensation™ technology. These scaleable devices use ultra-sensitive carbon nanotube detection elements combined with proprietary chemistries. They can be deployed across high value respiratory and biomarker detection applications where low power consumption, small size, and ultra-sensitivity offer significant performance advantages and enable unprecedented access to critical information. For additional information, please visit www.nano.com.

About MysticMD

MysticMD is an advanced materials company developing proprietary coating solutions using hybrid formulations of carbon nanotubes alloyed with traditional materials and other nano particles to solve real world problems. They are developing an intellectual property portfolio focused on dramatically improving their partners' products in key high value, high opportunity commercial applications. For more information, please visit http://www.mysticmd.com .

For more information, please click here

Contacts:
Nanomix, Inc.
Bill Perry
(510) 428-5300
Vice President

MysticMD Inc.
Heidi Douglas
(860) 961-8052
CEO

Copyright © Marketwire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Cloaked DNA nanodevices survive pilot mission: Successful foray opens door to virus-like DNA nanodevices that could diagnose diseased tissues and manufacture drugs to treat them April 22nd, 2014

Berkeley Lab Researchers Demonstrate First Size-based Chromatography Technique for the Study of Living Cells April 22nd, 2014

Amino-functionalized carbon nanotubes act as a carrier for nerve growth factor April 21st, 2014

Newly-Produced Bone Cement Able to Carry Medicine April 21st, 2014

Announcements

Berkeley Lab Researchers Demonstrate First Size-based Chromatography Technique for the Study of Living Cells April 22nd, 2014

PETA science consortium to present hazard testing strategy at nanotoxicology meeting: High tech field ripe for use of sophisticated non-animal testing strategies April 22nd, 2014

Harris & Harris Group Notes the Receipt of Proceeds From the Sale of Molecular Imprints' Semiconductor Business to Canon April 22nd, 2014

National Space Society Congratulates SpaceX on the Success of CRS-3 and the First Flight of the Falcon 9R April 22nd, 2014

Patents/IP/Tech Transfer/Licensing

Harris & Harris Group Notes Mersana's Collaboration Agreement With Subsidiary of Takeda Pharmaceutical Co. April 8th, 2014

Nanoparticles cause cancer cells to self-destruct April 3rd, 2014

A*STAR's Simtech collaboration agreements to accelerate the growth and development of the microfluidics industry April 1st, 2014

Dolomite releases novel droplet-on-demand sequencing and droplet generation microfluidic system April 1st, 2014

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE